Filing Details
- Accession Number:
- 0000950170-24-120231
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-01 20:59:16
- Reporting Period:
- 2024-10-30
- Accepted Time:
- 2024-11-01 20:59:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779308 | Catriona Yale | 601 Gateway Boulevard Suite 350 South San Francisco CA 94080 | Chief Development Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-10-30 | 4,515 | $21.10 | 78,673 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-10-30 | 4,515 | $32.53 | 74,158 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-11-01 | 15,485 | $21.10 | 89,643 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-11-01 | 15,485 | $32.62 | 74,158 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-30 | 4,515 | $0.00 | 4,515 | $21.10 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-01 | 15,485 | $0.00 | 15,485 | $21.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 57,266 | 2031-12-07 | No | 4 | M | Direct | |
| 41,781 | 2031-12-07 | No | 4 | M | Direct |
Footnotes
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated May 28, 2024, previously adopted by the Reporting Person.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $32.60, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $32.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- The options are vested and currently exercisable.
Billionaire Hedge Funds
